Lexeo Therapeutics, Inc.
LXEO
$5.09
-$0.41-7.46%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 62.33M | 63.80M | 65.95M | 73.68M | 75.52M |
| Gross Profit | -62.33M | -63.80M | -65.95M | -73.68M | -75.52M |
| SG&A Expenses | 35.46M | 45.46M | 47.57M | 49.74M | 40.76M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 97.79M | 109.26M | 113.52M | 123.42M | 116.28M |
| Operating Income | -97.79M | -109.26M | -113.52M | -123.42M | -116.28M |
| Income Before Tax | -87.50M | -99.96M | -104.97M | -114.17M | -109.31M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -87.50 | -99.96 | -104.97 | -114.17 | -109.31 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -87.50M | -99.96M | -104.97M | -114.17M | -109.31M |
| EBIT | -97.79M | -109.26M | -113.52M | -123.42M | -116.28M |
| EBITDA | -97.18M | -108.67M | -112.93M | -122.82M | -115.67M |
| EPS Basic | -1.45 | -2.19 | -2.70 | -3.26 | -3.31 |
| Normalized Basic EPS | -0.96 | -1.42 | -1.74 | -2.09 | -2.07 |
| EPS Diluted | -1.45 | -2.19 | -2.70 | -3.26 | -3.31 |
| Normalized Diluted EPS | -0.96 | -1.42 | -1.74 | -2.09 | -2.07 |
| Average Basic Shares Outstanding | 262.10M | 214.03M | 170.74M | 142.83M | 132.26M |
| Average Diluted Shares Outstanding | 262.10M | 214.03M | 170.74M | 142.83M | 132.26M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |